المؤلفون: Cançado, Guilherme Grossi Lopes, Deeb, Maya, Dodington, David, Hirschfield, Gideon Morris

المصدر: J Hepatol ; ISSN:1600-0641

مصطلحات موضوعية: Graft versus host disease, haemophagocytic lymphohistiocytosis, nodular regenerative hyperplasia, sinusoidal obstruction syndrome, venoocclusive disease

العلاقة: https://doi.org/10.1016/j.jhep.2024.04.005Test; https://pubmed.ncbi.nlm.nih.gov/38876804Test

الإتاحة: https://doi.org/10.1016/j.jhep.2024.04.005Test
https://pubmed.ncbi.nlm.nih.gov/38876804Test

المؤلفون: Akpınar, Seval, Kayıkçı, Ömür, Tekgündüz, Emre

مصطلحات موضوعية: Graft Versus Host Disease, Prevention, Defibrotide, Atg, Cyclophosphamide, Cyclosporine, Hepatic Venoocclusive Disease, Prophylaxis, Risk, Index, Leukemia

العلاقة: Transfusion and Apheresis Science; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1016/j.transci.2022.103367Test; https://hdl.handle.net/20.500.11776/10855Test; 61; WOS:000766631700010; 2-s2.0-85123891253

الإتاحة: https://doi.org/20.500.11776/10855Test
https://doi.org/10.1016/j.transci.2022.103367Test
https://hdl.handle.net/20.500.11776/10855Test

المؤلفون: Kayıkçı, Ömür, Akpınar, Seval, Tekgündüz, Emre

مصطلحات موضوعية: Hepatic Veno-Occlusive Disease, Sinusoidal Obstruction Syndrome, Hematopoietic Stem Cell Transplantation, Defibrotide, Prophylaxis, Venoocclusive Disease, Index, Diagnosis, Blood

العلاقة: Transfusion and Apheresis Science; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1016/j.transci.2022.103369Test; https://hdl.handle.net/20.500.11776/10874Test; 61; WOS:000766631700027; 2-s2.0-85123884447

الإتاحة: https://doi.org/20.500.11776/10874Test
https://doi.org/10.1016/j.transci.2022.103369Test
https://hdl.handle.net/20.500.11776/10874Test

المؤلفون: K. A. Sergeenko, T. Z. Aliev, I. O. Kostareva, Yu. V. Lozovan, M. D. Malova, N. A. Batmanova, T. T. Valiev, E. B. Machneva, K. I. Kirgizov, К. А. Сергеенко, Т. З. Алиев, И. О. Костарева, Ю. В. Лозован, М. Д. Малова, Н. А. Батманова, Т. Т. Валиев, Е. Б. Мачнева, К. И. Киргизов

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 9, № 2 (2022); 85-92 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 9, № 2 (2022); 85-92 ; 2413-5496 ; 2311-1267

مصطلحات موضوعية: блинатумомаб, inotuzumab ozogamicin, venoocclusive disease, minimal residual disease, blinatumomab, инотузумаб озогамицин, веноокклюзионная болезнь, минимальная остаточная болезнь

وصف الملف: application/pdf

العلاقة: https://journal.nodgo.org/jour/article/view/833/738Test; Bunn H.F., Aster J.C. Acute Leukemias. In: Pathophysiology of Blood Disorders. The McGraw-Hill Companies, Inc., 2011. Pp. 244–259.; Bhojwani D., Pui C.H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14:e205–17. doi:10.1016/S1470-2045(12)70580-6.; Sun W., Malvar J., Sposto R., Verma A., Wilkes J.J., Dennis R. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32(11):2316–25. doi:10.1038/s41375-018-0094-0.; Ko R.H., Ji L., Barnette P., Bostrom B., Hutchinson R., Raetz E. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28:648–54. doi:10.1200/JCO.2009.22.2950.; Dahl J., Marx K., Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol. 2016;9:329–34. doi:10.1586/17474086.2016.1143771.; Tedder T.F., Poe J.C., Haas K.M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005;88:1–50. doi:10.1016/S0065-2776(05)88001-0.; Shah N.N., Stevenson M.S., Yuan C.M., Richards K., Delbrook C., Kreitman R.J. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964–9. doi:10.1002/pbc.25410.; DeAngelo D.J., Stock W., Stein A.S., Shustov A., Liedtke M., Schiff er C.A. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–80. doi:10.1182/bloodadvances.2016001925.; Kantarjian H., Thomas D., Jorgensen J., Jabbour E., Kebriaei P., Rytting M. Inotuzumab ozogamicin, an anti-CD22- calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–11. doi:10.1016/S1470-2045(11)70386-2.; Benjamin J.E., Stein A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142–56. doi:10.1177/2040620716640422.; Locatelly F., Whitlock J., Peters C., Chen-Santel C., Chia V., Dennis R.M., Heym K.M., Katz A.J., Kelsh M.A., Sposto R., Tu H., Tuglus C.A., Verma A., Vinti L., Wilkes J.J., Zubarovskaja N., Zugmaier G., von Stackelberg A., Sun W. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34(9):2473–8. doi:10.1038/s41375-020-0770-8.; Батманова Н.А., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р. Применение блинатумомаба в терапии острого лимфобластного лейкоза у детей: особенности организации терапии, обеспечения препаратом и токсичность лечения. Обзор литературы и собственный опыт. Российский журнал детской гематологии и онкологии. 2021;8(4):39–46. doi:10.21682/2311-1267-2021-8-4-39-46.; Hoff man L.M., Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014;4:63. doi:10.3389/fonc.2014.00063.; Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334–42. doi:10.1016/j.pharmthera.2012.07.013.; von Stackelberg A., Locatelli F., Zugmaier G., Handgretinger R., Trippett T.M., Rizzari C., Bader P., OʼBrien M.M., Brethon B., Bhojwani D., Schlegel P.G., Borkhardt A., Rheingold S.R., Cooper T.M., Zwaan C.M., Barnette P., Messina C., Michel G., DuBois S.G., Hu K., Zhu M., Whitlock J.A., Gore L. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(36):4381–9. doi:10.1200/JCO.2016.67.3301.; Gokbuget N., Zugmaier G., Klinger M., Kufer P., Stelljes M., Viardot A., Horst H.A., Neumann S., Brüggemann M., Ottmann O.G., Burmeister T., Wessiepe D., Topp M.S., Bargou R. Long-term relapsefree survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102(4):e132–5. doi:10.3324/haematol.2016.153957.; Jasinski S., De Los Reyes F., Yametti G.C., Pierro J., Raetz E., Caroll W.L. Immunotherapy in pediatric B-acute lymphoblastic leukemia: Advances and ongoing challenges. Paediatr Drugs. 2020;22(5):485–99. doi:10.1007/s40272-020-00413-3.; Yurkiewicz I.R., Muffl y L., Liedtke M. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther. 2018;12:2293–300. doi:10.2147/DDDT.S150317.; DiJoseph J.F., Armellino D.C., Boghaert E.R., Khandke K., Dougher M.M., Sridharan L., Kunz A., Hamann P.R., Gorovits B., Udata C., Moran J.K., Popplewell A.G., Stephens S., Frost P., Damle N.K. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14. doi:10.1182/blood-2003-07-2466.; Shor B., Gerber H.P., Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67:107–16. doi:10.1016/j.molimm.2014.09.014.; Boue D.R., LeBien T.W. Expression and structure of CD22 in acute leukemia. Blood. 1988;71(5):1480–6. PMID: 3258772.; Thota S., Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425–34. doi:10.1111/ejh.12862.; Haso W., Lee D.W., Shah N.N., Stetler-Stevenson M., Yuan C.M., Pastan I.H., Dimitrov D.S., Morgan R.A., FitzGerald D.J., Barrett D.M., Wayne A.S., Mackall C.L., Orentas R.J. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165–74. doi:10.1182/blood-2012-06-438002.; De Vries J.F., Zwaan C.M., De Bie M., Voerman J.S.A., den Boer M.L., van Dongen J.J.M., van der Velden V.H.J. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) eff ectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–64. doi:10.1038/leu.2011.206.; Giles F.J., Kantarjian H.M., Kornblau S.M., Thomas D.A., Garcia-Manero G., Waddelow T.A., David C.L., Phan A.T., Colburn D.E., Rashid A., Estey E.H. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13. doi:10.1002/10970142(20010715)92:23.0.co;2-u.; McKoy J.M., Angelotta C., Bennett C.L., Tallman M.S., Wadleigh M., Evens A.M., Kuzel T.M., Trifi lio S.M., Raisch D.W., Kell J., DeAngelo D.J., Giles F.J. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604. doi:10.1016/j.leukres.2006.07.005.; Godwin C.D., McDonald G.B., Walter R.B. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood. 2017;129(16):2330–2. doi:10.1182/blood-2017-01-762419.; Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., Stock W., Gökbuget N., O’Brien S., Wang K., Wang T., Paccagnella M.L., Sleight B., Vandendries E., Advani A.S. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53. doi:10.1056/NEJMoa1509277.; Pfi zer Ltd. BESPONSA™ (inotuzumab ozogamicin) summary of product characteristics, 2020.; Lamb Y.N. Inotuzumab Ozogamicin: First Global Approval. Drugs. 2017;77(14):1603–10. doi:10.1007/s40265-017-0802-5.; Rytting M., Triche L., Thomas D. Initial experience with CMC544 (inotuzumab ozogamicin) in pediatric patients with relapsed B cell acute lymphoblastic leukemia. Pediatr Blood. 2014;544:369–72. doi:10.1002/pbc.24721.; Bhojwani D., Sposto R., Shah N.N., Rodriguez V., Yuan C., Stetler-Stevenson M., O’Brien M.M., McNeer J.L., Quereshi A., Cabannes A., Schlegel P., Rossig C., Dalla-Pozza L., August K., Alexander S., Bourquin J.-P., Zwaan M., Raetz E.A., Loh M.L., Rheingold S.R. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2018;33(4):884–92. doi:10.1038/s41375-018-0265-z.; https://journal.nodgo.org/jour/article/view/833Test

الإتاحة: https://doi.org/10.21682/2311-1267-2022-9-2-85-92Test
https://doi.org/10.1016/S1470-2045Test(12)70580-6
https://doi.org/10.1200/JCO.2009.22.2950Test
https://doi.org/10.1586/17474086.2016.1143771Test
https://doi.org/10.1016/S0065-2776Test(05)88001-0
https://doi.org/10.1002/pbc.25410Test
https://doi.org/10.1182/bloodadvances.2016001925Test
https://doi.org/10.1016/S1470-2045Test(11)70386-2
https://doi.org/10.1177/2040620716640422Test
https://doi.org/10.1038/s41375-020-0770-8Test

المؤلفون: Certain, Marie-Caroline, Chaumais, Marie-Camille, Jaïs, Xavier, Savale, Laurent, Seferian, Andrei, Parent, Florence, Georges, Marjolaine, Favrolt, Nicolas, Bourdin, Arnaud, Boissin, Clément, Cottin, Vincent, Traclet, Julie, Renard, Sébastien, Noel, Violaine, Picard, François, Girerd, Barbara, Marie-Rosa, Ghigna, Perros, Frédéric, Sitbon, Olivier, Bonniaud, Philippe, Humbert, Marc, Montani, David

المساهمون: Service de Pneumologie Soins Intensifs, Appareillage Respiratoire CHU de Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Dijon, Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) (CRMR des maladies pulmonaires rares de l’adulte), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Chirurgical Marie Lannelongue (CCML), Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Saclay, Université Bourgogne Franche-Comté COMUE (UBFC), Lipides - Nutrition - Cancer Dijon - U1231 (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel CHU - HCL, Hospices Civils de Lyon (HCL), Hôpital de la Timone CHU - APHM (TIMONE), Hôpital Robert Debré, Hôpital Robert Debré-Hôpital universitaire Robert Debré Reims (CHU Reims), CHU Bordeaux

المصدر: ISSN: 0012-3692.

مصطلحات موضوعية: mitomycin Cpharmacovigilance, pulmonary hypertension, pulmonary venoocclusive disease, [SDV]Life Sciences [q-bio]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32979348; hal-02956364; https://hal.science/hal-02956364Test; https://hal.science/hal-02956364/documentTest; https://hal.science/hal-02956364/file/2020%20Certain%20et%20al.,%20Characteristics%20and.pdfTest; PUBMED: 32979348; WOS: 000632456400051

الإتاحة: https://doi.org/10.1016/j.chest.2020.09.238Test
https://hal.science/hal-02956364Test
https://hal.science/hal-02956364/documentTest
https://hal.science/hal-02956364/file/2020%20Certain%20et%20al.,%20Characteristics%20and.pdfTest

المؤلفون: Ruutu, Tapani, van der Werf, Steffie, van Biezen, Anja, Backman, Janne T., Peczynski, Christophe, Kröger, Nicolaus, Mohty, Mohamad, Nagler, Arnon, Montoto, Silvia, Langebrake, Claudia, Niederwieser, Dietger, Peric, Zinaida, Koenecke, Christian, Duarte, Rafael F., Basak, Grzegorz

المساهمون: HUS Comprehensive Cancer Center, Department of Medicine, HUSLAB, Department of Clinical Pharmacology, Janne Backman / Principal Investigator, University Management, University of Helsinki

مصطلحات موضوعية: DAILY IV BUSULFAN, CHEMOTHERAPY DOSE ADJUSTMENT, BONE-MARROW TRANSPLANTATION, DAILY INTRAVENOUS BUSULFAN, VENOOCCLUSIVE DISEASE, AMERICAN SOCIETY, EUROPEAN-SOCIETY, OBESE-PATIENTS, EXPOSURE, PHARMACOKINETICS, 3122 Cancers, 3121 General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

العلاقة: Ruutu , T , van der Werf , S , van Biezen , A , Backman , J T , Peczynski , C , Kröger , N , Mohty , M , Nagler , A , Montoto , S , Langebrake , C , Niederwieser , D , Peric , Z , Koenecke , C , Duarte , R F & Basak , G 2019 , ' Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults : a survey by the Transplant Complications Working Party of the EBMT ' , Bone Marrow Transplantation , vol. 54 , no. 12 , pp. 2013-2019 . https://doi.org/10.1038/s41409-019-0579-0Test; ORCID: /0000-0002-9577-2788/work/68613616; 44bebebe-b215-46b4-ade1-3cf6e2e45c06; http://hdl.handle.net/10138/325356Test; 000500920000013

الإتاحة: http://hdl.handle.net/10138/325356Test

المؤلفون: Flavio Bonanini, Dorota Kurek, Sara Previdi, Arnaud Nicolas, Delilah Hendriks, Sander de Ruiter, Marine Meyer, Maria Clapés Cabrer, Roelof Dinkelberg, Silvia Bonilla García, Bart Kramer, Thomas Olivier, Huili Hu, Carmen López-Iglesias, Frederik Schavemaker, Erik Walinga, Devanjali Dutta, Karla Queiroz, Karel Domansky, Bob Ronden, Jos Joore, Henriette L. Lanz, Peter J. Peters, Sebastiaan J. Trietsch, Hans Clevers, Paul Vulto

المساهمون: RS: M4I - Nanoscopy, Institute of Nanoscopy (IoN), Hubrecht Institute for Developmental Biology and Stem Cell Research

المصدر: Angiogenesis
Angiogenesis, 25(4), 455-470. Springer, Cham
Angiogenesis, 25(4), 455-470. Springer Netherlands

مصطلحات موضوعية: Cancer Research, ORGANOGENESIS, Physiology, Vascularization, Microfluidics, Clinical Biochemistry, FUNCTIONAL HUMAN LIVER, PHENOTYPE, ANGIOGENESIS, Coculture Techniques, CULTURE, Organoids, VENOOCCLUSIVE DISEASE, HUMAN HEPATOCYTES, Liver, TISSUE, Azathioprine, Liver organoids and spheroids, Animals, Humans, In vitro grafting, Microfluidics/methods, SINUSOIDAL ENDOTHELIAL-CELLS

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63ec0a48cd9e53cc433f25ac1e44dc3Test
https://hdl.handle.net/20.500.11755/2f4b45f1-2d58-4417-9e79-555cb1fb13caTest

المؤلفون: Mohty, Mohamad, Malard, Florent, Abecasis, Manuel, Aerts, Erik, Alaskar, Ahmed S., Aljurf, Mahmoud, Arat, Mutlu, Bader, Peter, Baron, Frederic, Basak, Grzegorz, Bazarbachi, Ali, Blaise, Didier, Ciceri, Fabio, Corbacioglu, Selim, Dalle, Jean-Hugues, Dignan, Fiona, Fukuda, Takahiro, Huynh, Anne, Kuball, Jurgen, Lachance, Silvy, Lazarus, Hillard, Masszi, Tamas, Michallet, Mauricette, Nagler, Arnon, NiChonghaile, Mairead, Okamoto, Shinichiro, Pagliuca, Antonio, Peters, Christina, Petersen, Finn B., Richardson, Paul G., Ruutu, Tapani, Saber, Wael, Savani, Bipin N., Soiffer, Robert, Styczynski, Jan, Wallhult, Elisabeth, Yakoub-Agha, Ibrahim, Duarte, Rafael F., Carreras, Enric

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Hematologian yksikkö

مصطلحات موضوعية: HEPATIC VENOOCCLUSIVE DISEASE, STEM-CELL TRANSPLANTATION, BONE-MARROW-TRANSPLANTATION, HAPLOIDENTICAL DONOR TRANSPLANTATION, REGIMEN-RELATED TOXICITIES, URSODEOXYCHOLIC ACID, PERIPHERAL-BLOOD, EUROPEAN-SOCIETY, RANDOMIZED-TRIAL, PD-1 BLOCKADE, 3122 Cancers

وصف الملف: application/pdf

العلاقة: MM thanks Prof. Junia V. Melo (University of Adelaide, Australia) for critical reading of the manuscript. This work was made possible thanks to the support of the Association for Training, Education, Research, in Hematology, Immunology and Transplantation (ATHERIT), which received an unrestricted educational grant from JAZZ pharmaceuticals. However JAZZ pharmaceuticals did not participate in its execution, data/result analyses, or manuscript writing or reviewing.; Mohty , M , Malard , F , Abecasis , M , Aerts , E , Alaskar , A S , Aljurf , M , Arat , M , Bader , P , Baron , F , Basak , G , Bazarbachi , A , Blaise , D , Ciceri , F , Corbacioglu , S , Dalle , J-H , Dignan , F , Fukuda , T , Huynh , A , Kuball , J , Lachance , S , Lazarus , H , Masszi , T , Michallet , M , Nagler , A , NiChonghaile , M , Okamoto , S , Pagliuca , A , Peters , C , Petersen , F B , Richardson , P G , Ruutu , T , Saber , W , Savani , B N , Soiffer , R , Styczynski , J , Wallhult , E , Yakoub-Agha , I , Duarte , R F & Carreras , E 2020 , ' Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group ' , Bone Marrow Transplantation , vol. 55 , no. 3 , pp. 485-495 . https://doi.org/10.1038/s41409-019-0705-zTest; 29778c66-946f-4e47-b2c2-33f12bfb4b36; http://hdl.handle.net/10138/313991Test; 000519447100004

الإتاحة: http://hdl.handle.net/10138/313991Test

المؤلفون: Marie-Caroline Certain, David Montani, Arnaud Bourdin, Vincent Cottin, Marjolaine Georges, Florence Parent, Marie-Camille Chaumais, Sébastien Renard, Violaine Noel, François Picard, Andrei Seferian, Barbara Girerd, Laurent Savale, Nicolas Favrolt, Olivier Sitbon, Xavier Jaïs, Marc Humbert, Clément Boissin, Philippe Bonniaud, Julie Traclet, Frédéric Perros, Maria-Rosa Ghigna

المساهمون: Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Dijon, Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) (CRMR des maladies pulmonaires rares de l’adulte), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre chirurgical Marie Lannelongue, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris-Saclay, Université Bourgogne Franche-Comté [COMUE] (UBFC), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Bordeaux [Bordeaux]

المصدر: Chest
Chest, American College of Chest Physicians, 2021, 159 (3), pp.1197-1207. ⟨10.1016/j.chest.2020.09.238⟩

مصطلحات موضوعية: Male, Pulmonary and Respiratory Medicine, Cardiac Catheterization, Pulmonary Circulation, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Hypertension, Pulmonary, Mitomycin, Critical Care and Intensive Care Medicine, Pulmonary vein, Pharmacovigilance, 03 medical and health sciences, 0302 clinical medicine, DLCO, medicine.artery, Internal medicine, pulmonary hypertension, medicine, Humans, Pulmonary Wedge Pressure, Registries, 030212 general & internal medicine, Pulmonary wedge pressure, Lung, mitomycin Cpharmacovigilance, Antibiotics, Antineoplastic, pulmonary venoocclusive disease, business.industry, Middle Aged, Prognosis, Pulmonary edema, medicine.disease, Survival Analysis, Pulmonary hypertension, Patient Care Management, 3. Good health, Functional Status, medicine.anatomical_structure, Withholding Treatment, 030228 respiratory system, Pulmonary venoocclusive disease, Pulmonary artery, Vascular resistance, Cardiology, Pulmonary Veno-Occlusive Disease, Female, France, Cardiology and Cardiovascular Medicine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bd619ffd3ec7b1d51821c78bba344bTest
https://doi.org/10.1016/j.chest.2020.09.238Test

المؤلفون: Corbacioglu S., Carreras E., Ansari M., Balduzzi A., Cesaro S., Dalle J. -H., Dignan F., Gibson B., Guengoer T., Gruhn B., Lankester A., Locatelli F., Pagliuca A., Peters C., Richardson P. G., Schulz A. S., Sedlacek P., Stein J., Sykora K. -W., Toporski J., Trigoso E., Vetteranta K., Wachowiak J., Wallhult E., Wynn R., Yaniv I., Yesilipek A., Mohty M., Bader P.

المساهمون: Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J. -H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., Lankester, A., Locatelli, F., Pagliuca, A., Peters, C., Richardson, P. G., Schulz, A. S., Sedlacek, P., Stein, J., Sykora, K. -W., Toporski, J., Trigoso, E., Vetteranta, K., Wachowiak, J., Wallhult, E., Wynn, R., Yaniv, I., Yesilipek, A., Mohty, M., Bader, P.

مصطلحات موضوعية: hepatic venoocclusive disease, stem-cell transplantation, acute lymphoblastic-leukemia

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28759025; info:eu-repo/semantics/altIdentifier/wos/WOS:000424358300005; volume:53; issue:2; firstpage:138; lastpage:145; numberofpages:8; journal:BONE MARROW TRANSPLANTATION; http://hdl.handle.net/11573/1479690Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85041353436

الإتاحة: https://doi.org/10.1038/bmt.2017.161Test
http://hdl.handle.net/11573/1479690Test